about
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionStatins for children with familial hypercholesterolemiaStatins for the treatment of dementiaFibrates for type 2 diabetes mellitusFibrates for type 2 diabetes mellitusStatins for children with familial hypercholesterolemiaFibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap)GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushingCholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigsNonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB CouncilFibroblast growth factors in cardiovascular disease: The emerging role of FGF21Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?Lipid-lowering update 2001. Aggressive new goalsThe severity of the metabolic syndrome increases over time within individuals, independent of baseline metabolic syndrome status and medication use: The Atherosclerosis Risk in Communities Study.Molecular imaging in atherosclerosis.Effect of niacin on the choroidal circulation of patients with age related macular degenerationEffectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data.Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.The pros and the cons of mTOR inhibitors in kidney transplantation.Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3.Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment.Hyperlipidemia medication management in patients admitted for a myocardial infarction.Coronary artery disease and human immunodeficiency virus infection.NK-104: a novel synthetic HMG-CoA reductase inhibitor.Effectiveness of altering serum cholesterol levels without drugs.Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction.Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in GermanyHigh density lipoproteins-based therapies for cardiovascular disease.Sudden infant death syndrome and other causes of infant mortality: diagnosis, mechanisms, and risk for recurrence in siblings.Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States.Statins and progressive renal disease.Strategies for treating HIV-related lipodystrophy.Statin-induced myopathy: the two faces of Janus.Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.Statins: balancing benefits, efficacy and safety.Cholesterol absorption inhibitors in development as potential therapeutics.Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.Management of dyslipidemia in women in the post-hormone therapy era.
P2860
Q21246041-4098FDED-E5CF-4884-B398-62F85FF012A4Q24194816-A7ADB576-1F24-46DB-AAC3-DF257B110FD5Q24194901-1E0C84D6-3514-4B21-A723-A340EBA1A0E0Q24195161-CE08D3AF-E2AB-464A-9FB2-F24688007F64Q24204016-8022921C-0A11-4610-B509-AEBBD01C4CD2Q24234081-3764F6C0-9F3D-4AE9-AA7E-3467E9E5726CQ24306597-AF4C1E19-2AFA-4294-A3B4-0BC80F43509CQ24536109-3D58D79A-70F0-4E2F-AF61-C2000CE9B87EQ24804269-04E18E8A-3150-499E-87BF-8870A3D2A298Q28084156-2C5EFDF3-B20E-48FD-9DEA-99FE4C10E5BCQ28084197-3C39F1B2-4BAE-4085-87A1-95E6852885C1Q28220294-993180B1-4604-4C3E-ACDD-991CB227F2DAQ28222549-53C6F9FE-6B02-4159-88B1-02128C54824EQ28354365-F448BBFE-A25F-4099-B057-B87B4CC154F1Q30278617-23ADDB68-9942-4561-B3B0-3EA7F7F0809FQ30478541-59B26C57-839D-4F16-87FF-B0415F4202E7Q31129710-3C747576-4F3E-4CD1-8E11-48AF1B8BC277Q31129888-2465B446-B256-44B9-9DFE-8258B2CDC1D7Q31989536-EFCC0BE3-6AAB-4F38-A83D-266E58B18412Q33412367-6C81C70F-E169-4CB4-B72B-ED902879D3F5Q33938868-18C17850-4AB4-477D-AE3D-E844E645BD70Q33991193-4BA0D6E4-199E-43B2-9A51-2231C95E9417Q34007479-E25EB347-1890-4740-82C4-D5C927D77359Q34045514-44C45D03-C53F-4DF1-BA80-4491456141C8Q34052597-726F005F-2016-40BF-99E3-2CE55E4D6792Q34075186-6DDE5376-A16C-4EA6-9EDA-E7FC1730CFF3Q34212139-2A06D76A-C4D6-4142-B02A-159E7230D25FQ34219115-71C5E923-02F3-4DC3-9420-D2AF20F35584Q34222469-C9A6BAE5-7973-4AB5-8A41-29FFF1E2852AQ34313937-AC28F8D4-0D58-40CD-A614-AEC97CE9B1F9Q34334114-845E318D-D64C-4778-8017-4F0C8814B804Q34350375-57C52908-0A30-4FF8-A33A-5044B7C22DABQ34464593-E605CC7F-D2C6-4D85-B9DA-F30036DE7138Q34481623-7EEAB318-8BCD-421A-ACB2-2E63D54FBAC4Q34554637-8A2586DC-8B2A-438B-8C83-EE85CBCE9546Q34596247-4C66F766-822F-4998-AFD0-CECF7F623448Q34628565-D8C11821-FB19-4CE0-B065-2C0CFE6108FDQ34660878-825ABFE3-4DB3-4409-A4F1-2227353D97DEQ34687470-FF00EEE6-B249-4045-8F26-D0EBD1E4C9E7Q34722828-BF179679-DF52-4F16-AC31-A64829A049BD
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Drug treatment of lipid disorders.
@ast
Drug treatment of lipid disorders.
@en
type
label
Drug treatment of lipid disorders.
@ast
Drug treatment of lipid disorders.
@en
prefLabel
Drug treatment of lipid disorders.
@ast
Drug treatment of lipid disorders.
@en
P1476
Drug treatment of lipid disorders.
@en
P2093
P304
P356
10.1056/NEJM199908123410707
P407
P577
1999-08-01T00:00:00Z